ResMed Inc. · NYSE (us_market)
Healthcare · Medical Instruments & Supplies · United States
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-01-30$257.65 RISE2025-04-08$204.54 PEAK2025-06-30$258.00 151d | -20.6% 68d | Missed | Missed | — | — | +26.1% 83d | Missed |
DROP2024-05-15$220.63 RISE2024-06-24$182.20 PEAK2024-09-11$252.92 119d | -17.4% 40d | Missed | Missed | — | — | +38.8% 79d | Missed |
DROP2023-08-01$225.35 RISE2023-10-27$134.65 PEAK2024-01-25$186.35 177d | -40.2% 87d | 2023-09-05 $153.89 | 2024-01-25 $186.35 | 62Quality on Sale | 54Watch | +38.4% 90d | +21.1% Held 142d |
DROP2023-05-12$233.50 RISE2023-09-21$136.29 PEAK2023-12-14$172.64 216d | -41.6% 132d | 2023-09-05 $153.89 | 2023-12-14 $172.64 | 62Quality on Sale | 58Watch | +26.7% 84d | +12.2% Held 100d |
DROP2022-03-18$261.47 RISE2022-05-18$191.41 PEAK2022-08-10$243.58 145d | -26.8% 61d | Missed | Missed | — | — | +27.3% 84d | Missed |
DROP2021-09-22$288.48 RISE2022-01-28$216.12 PEAK2022-03-18$261.47 177d | -25.1% 128d | Missed | Missed | — | — | +21.0% 49d | Missed |
DROP2021-01-26$222.28 RISE2021-04-30$187.97 PEAK2021-07-27$264.24 182d | -15.4% 94d | Missed | Missed | — | — | +40.6% 88d | Missed |
DROP2021-01-26$222.28 RISE2021-03-08$179.46 PEAK2021-04-26$210.89 90d | -19.3% 41d | Missed | Missed | — | — | +17.5% 49d | Missed |
DROP2020-07-27$205.63 RISE2020-10-02$167.50 PEAK2020-11-09$220.59 105d | -18.5% 67d | Missed | Missed | — | — | +31.7% 38d | Missed |
DROP2020-02-19$176.62 RISE2020-03-20$114.34 PEAK2020-05-11$169.28 82d | -35.3% 30d | Missed | Missed | — | — | +48.0% 52d | Missed |
ResMed continues to command steady Wall Street confidence despite recent stock pressure and a few bumps along the road.
ResMed continues to command steady Wall Street confidence despite recent stock pressure and a few bumps along the road.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 1.8% return has trailed the S&P 500 by 9 percentage points.
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloaded surplus COVID inventories in 2023 and 2024, a headwind for overall demand. The result? Over the past six months, the industry’s 1.8% return has trailed the S&P 500 by 9 percentage points.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new areas for growth is much harder than for smaller, more agile players.
ResMed recently announced a collaboration with ŌURA that connects Oura Ring members in the U.S. to ResMed’s sleep education tools, assessments, and options to engage independent healthcare providers for potential conditions such as obstructive sleep apnea. This partnership links consumer wearables with clinical sleep pathways, potentially widening the funnel from at-home tracking to medically supervised diagnosis and treatment. We’ll now examine how integrating ŌURA’s wearable sleep insights...
ResMed recently announced a collaboration with ŌURA that connects Oura Ring members in the U.S. to ResMed’s sleep education tools, assessments, and options to engage independent healthcare providers for potential conditions such as obstructive sleep apnea. This partnership links consumer wearables with clinical sleep pathways, potentially widening the funnel from at-home tracking to medically supervised diagnosis and treatment. We’ll now examine how integrating ŌURA’s wearable sleep insights...
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
Investors need to pay close attention to RMD stock based on the movements in the options market lately.
ResMed (RMD) is in focus after announcing a collaboration with Oura that connects Oura Ring users in the US to ResMed’s sleep education tools, assessments, and potential care pathways for obstructive sleep apnea. See our latest analysis for ResMed. The collaboration with Oura lands at a time when momentum in ResMed’s share price has cooled, with the stock down about 19.8% on a 90-day share price return and its 1-year total shareholder return down around 15.5%, even after a recent 1-week share...
ResMed (RMD) is in focus after announcing a collaboration with Oura that connects Oura Ring users in the US to ResMed’s sleep education tools, assessments, and potential care pathways for obstructive sleep apnea. See our latest analysis for ResMed. The collaboration with Oura lands at a time when momentum in ResMed’s share price has cooled, with the stock down about 19.8% on a 90-day share price return and its 1-year total shareholder return down around 15.5%, even after a recent 1-week share...
SAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Aaron Bloomer, chief financial officer, will attend the 46th Annual William Blair Growth Stock Conference in Chicago, IL on Tuesday, June 2, 2026. Resmed’s webcast presentation will begin at approximately 4:40 p.m. (Central Time). More information about this event, including access to the live, audio-only webcast, may be accessed by visiting https://inv
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Healthcare giants like Eli Lilly, Tandem Diabetes, Intuitive Surgical and ResMed are tapping aging-driven demand in obesity, surgery and sleep care.
Oura Members can take action on changes in sleep or breathing patterns through educational resources from Resmed and pathways for accessing careSAN DIEGO, May 19, 2026 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, and ŌURA, maker of the world’s leading smart ring, today announced they are partnering to expand access to sleep health education and pathways to care, helping more people sleep better
Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]
Danaher Corporation (NYSE:DHR) was one of the stocks on which Jim Cramer shared his take, explaining that dot-com analogies do not hold up in this market. Cramer called it a “one-time excellent company,” as he said: For instance, Danaher, another one-time excellent company, has seen the stock just get pulverized after not-so-great quarters, or I […]
Discover the top S&P500 movers in Wednesday's after-hours session and stay informed about the post-market dynamics.
Jim Cramer says investors are aggressively favoring AI stocks while heavily punishing companies that disappoint Wall Street.
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| RMD | -7.05% | -25.96% | -20.88% | -22.15% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -10.02% | -20.25% | -17.44% | -34.84% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| StateStreet | passive | 6.64M | $1.49B | 0.05% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 343.6K | $77.14M | 0.00% | Trimmed-17.4% | 2026-03-31 |
| TwoSigma | quant | 312.5K | $70.14M | 0.06% | New | 2026-03-31 |
| Wellington | fundamental | 59.7K | $13.39M | 0.00% | Trimmed-19.2% | 2026-03-31 |
| Bridgewater | macro | 39.2K | $8.81M | 0.04% | Added+19.2% | 2026-03-31 |
| DEShaw | quant | 11.6K | $2.60M | 0.00% | Trimmed-50.9% | 2026-03-31 |
| TRowePrice | fundamental | 472.6K | $106.09K | 0.01% | Trimmed-38.7% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-11 | Farrell Michael J. | Chairman and CEO | M Option exercise(deriv) | 4,991 | — | +$0 |
| 2026-05-11 | Farrell Michael J. | Chairman and CEO | S Open-market sale | 4,991 | $207.82 | −$1.04M |
| 2026-05-11 | Farrell Michael J. | Chairman and CEO | M Option exercise | 4,991 | $146.34 | +$730.4K |
| 2026-04-09 | Farrell Michael J. | Chairman and CEO | M Option exercise(deriv) | 4,991 | — | +$0 |
| 2026-04-09 | Farrell Michael J. | Chairman and CEO | S Open-market sale | 4,991 | $225.50 | −$1.13M |
| 2026-04-09 | Farrell Michael J. | Chairman and CEO | M Option exercise | 4,991 | $146.34 | +$730.4K |
| 2026-04-03 | Sandercock Brett | Chief Financial Officer | S Open-market sale | 1,000 | $224.31 | −$224.3K |
| 2026-04-02 | FARRELL PETER C | Director | S Open-market sale | 2,000 | $225.00 | −$450.0K |
| 2026-03-11 | Farrell Michael J. | Chairman and CEO | M Option exercise(deriv) | 4,991 | — | +$0 |
| 2026-03-11 | Farrell Michael J. | Chairman and CEO | S Open-market sale | 4,991 | $251.03 | −$1.25M |
| 2026-03-11 | Farrell Michael J. | Chairman and CEO | M Option exercise | 4,991 | $146.34 | +$730.4K |
| 2026-03-05 | FARRELL PETER C | Director | S Open-market sale | 2,000 | $260.22 | −$520.4K |
| 2026-03-03 | Sandercock Brett | Chief Financial Officer | S Open-market sale | 1,000 | $254.30 | −$254.3K |
| 2026-02-10 | Farrell Michael J. | Chairman and CEO | M Option exercise(deriv) | 4,991 | — | +$0 |
| 2026-02-10 | Farrell Michael J. | Chairman and CEO | S Open-market sale | 4,991 | $273.78 | −$1.37M |
| 2026-02-10 | Farrell Michael J. | Chairman and CEO | M Option exercise | 4,991 | $146.34 | +$730.4K |
| 2026-02-06 | Rider Michael J | Global General Counsel | S Open-market sale | 50 | $260.00 | −$13.0K |
| 2026-02-06 | FARRELL PETER C | Director | S Open-market sale | 2,000 | $251.31 | −$502.6K |
| 2026-02-03 | Sandercock Brett | Chief Financial Officer | S Open-market sale | 1,000 | $257.03 | −$257.0K |
| 2026-01-09 | FARRELL PETER C | Director | S Open-market sale | 2,000 | $248.83 | −$497.7K |
| 2026-01-08 | Farrell Michael J. | Chairman and CEO | M Option exercise(deriv) | 4,991 | — | +$0 |
| 2026-01-08 | Farrell Michael J. | Chairman and CEO | S Open-market sale | 4,991 | $248.46 | −$1.24M |
| 2026-01-08 | Farrell Michael J. | Chairman and CEO | M Option exercise | 4,991 | $146.34 | +$730.4K |
| 2026-01-05 | Rider Michael J | Global General Counsel | S Open-market sale | 50 | $241.75 | −$12.1K |
| 2026-01-05 | Sandercock Brett | Chief Financial Officer | S Open-market sale | 1,000 | $241.75 | −$241.8K |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | 2.90 | — | — |
| 2026-04-30 | 2.80 | 2.86 | +2.15% |
| 2026-01-29 | 2.72 | 2.81 | +3.15% |
| 2025-10-30 | 2.50 | 2.55 | +2.05% |
| 2025-07-31 | 2.48 | 2.55 | +2.77% |
| 2025-04-23 | 2.36 | 2.37 | +0.41% |
| 2025-01-30 | 2.31 | 2.43 | +4.98% |
| 2024-10-24 | 2.04 | 2.20 | +7.69% |
| 2024-08-01 | 2.07 | 2.08 | +0.52% |
| 2024-04-25 | 1.91 | 2.13 | +11.68% |
| 2024-01-24 | 1.78 | 1.88 | +5.45% |
| 2023-10-26 | 1.61 | 1.64 | +1.68% |
| 2023-08-03 | 1.69 | 1.60 | -5.38% |
| 2023-04-27 | 1.59 | 1.68 | +5.48% |
| 2023-01-26 | 1.62 | 1.66 | +2.62% |
| 2022-10-27 | 1.60 | 1.51 | -5.68% |